Skip to main content

Table 1 Baseline characteristics of patients included in this post-hoc analysis of the Sharafkhaneh et al. study [16]

From: Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

 

BUD/FORM

FORM

Total

(n = 407)

(n = 403)

(n = 810)

Male, n (%)

262 (64.4)

229 (56.8)

491 (60.6)

Age, years (range)

63.8 (40–86)

62.5 (40–87)

63.2 (40–87)

Pre-BD FEV1, % predicted

33.0 (10.5)

32.4 (10.1)

32.7 (10.3)

Post-BD FEV1, % predicted

37.9 (11.8)

37.5 (12.4)

37.7 (12.1)

Pre-BD FEV1/FVC ratio, %

45.9 (11.3)

46.1 (11.1)

46.0 (11.2)

Smoking history

 Current smokers, n (%)

138 (33.9)

154 (38.2)

292 (36.0)

 Pack-years (range)

52.6 (10–200)

52.2 (10–258)

52.4 (10–258)

Most common COPD medications before run-in, n (%)

 β2-adrenergic agonists (SABA/LABA)

320 (78.6)

321 (79.7)

641 (79.1)

 Adrenergics/other drugs for obstructive airway diseases

198 (48.6)

196 (48.6)

394 (48.6)

 Long-acting muscarinic antagonist

123 (30.2)

109 (27.0)

232 (28.6)

 Inhaled corticosteroids

108 (26.5)

117 (29.0)

225 (27.8)

No. of exacerbations in the past 12 months, n (%)

 1

244 (60.0)

234 (58.1)

478 (59.0)

 2

95 (23.3)

99 (24.6)

194 (24.0)

 3

36 (8.8)

38 (9.4)

74 (9.1)

 4

22 (5.4)

19 (4.7)

41 (5.1)

  ≥ 5

10 (2.5)

13 (3.2)

23 (2.8)

Mean reliever use, inhalations/daya

5.8 (4.6)

6.0 (4.5)

5.9 (4.6)

Patients taking ICS at baseline, n %

108 (26.5)

117 (29.0)

225 (2.8)

  1. Data shown as mean (±SD), unless otherwise stated. Current smokers include habitual and occasional smokers
  2. BD bronchodilator, BUD budesonide, FEV 1 forced expiratory volume in 1 s, FORM formoterol, FVC forced vital capacity, ICS inhaled corticosteroid, LABA long-acting β2-agonists, SABA short-acting β2-agonists, SD standard deviation
  3. aBaseline: 2-week run-in period